Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLOW5: Glycopyrronium vs Tiotropium in COPD
NCT01613326Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2012
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Novartis. Started Jun 2012; status: completed.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01613326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01613326.